Home
PODCAST
TOP INDUSTRY NEWS
-
Novartis Completes Acquisition of Regulus Therapeutics in $1.7 Bn Deal
-
Supplier News: AGC Biologics, Samsung Biologics, Bend Bioscience & More
-
Partnering News: Gilead, Roche & More
-
Global Briefs: Incyte, CDC, Bavarian Nordic & More
-
FDA Launches Commissioner’s National Priority Voucher To Expedite Drug Reviews
-
Cell and Gene Therapies: How is the Market Faring?
Cell and gene therapies are a niche segment in the global bio/pharmaceutical market. What are leading products, and what are key developments thus far in 2025?
-
Productivity, Wages, and AI: A Plus or Minus?
A recent PwC analysis examined the impact of productivity, wages, and overall value in industries with strong and limited exposure to AI. What did it find?
-
Will New Oral GLP-1 Agonists Be the Next Market Shaker?
The blockbuster success of Novo Nordisk’s Ozempic/Wegovy and Lilly’s Mounjaro/Zepbound, all injectables, have put GLP-1/GIP agonists on the map, but will new oral drugs be a game-changer?
DCAT MEMBER COMPANY COMMUNITY
-
DCAT Awards Grants To Student Scientists at the 2025 Regeneron International Science & Engineering Fair
The Drug, Chemical & Associated Technologies Association (DCAT) has awarded $30,000 in grants to student scientists of four projects who participated in the Regeneron International Science & Engineering Fair (Regeneron…
-
ICYMI: DCAT Production to Prescription Podcast: “Headwinds or Tailwinds: Will the Biotech Sector Rebound in 2025?”
Biotech companies are an important source for innovation and product development for larger companies and are an important customer base of CDMOs/CMOs. Capital flow in the biotech sector, a key…
-
People on the Move
Here are the latest moves and promotions of employees from the DCAT Member Company community. To submit a request to be included in People on the Move, click here. From the…
-
New Podcast Episode! Biomanufacturing: How are Industry Capacity & Supply Chains Trending?
What is industry capacity utilization for biomanufacturing among the major systems/platforms (mammalian, microbial, and advanced therapies)? Is there too much capacity or is the market tight? The latest episode of…
